A neoantigen vaccine generates antitumour immunity in renal cell carcinoma.

ABSTRACT: Personalized cancer vaccines (PCVs) can generate circulating immune responses against predicted neoantigens^1-6. However, whether such responses can target cancer driver mutations, lead to immune recognition of a patient's tumour and result in clinical activity are largely unknown. These questions are of particular interest for patients who have tumours with a low mutational burden. Here we conducted a phase I trial (ClinicalTrials.gov identifier NCT02950766) to test a neoantigen-targeting PCV in patients with high-risk, fully resected clear cell renal cell carcinoma (RCC; stage III or IV) with or without ipilimumab administered adjacent to the vaccine. At a median follow-up of 40.2 months after surgery, none of the 9 participants enrolled in the study had a recurrence of RCC. No

SUBMITTER: Braun DA 

PROVIDER: S-EPMC11903305 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature